George Goshua, EHA 2020: Endotheliopathy is Essential in COVID-19 Associated Coagulopathy
Access all of the content
Dr George Goshua (Yale University School of Medicine, New Haven, CT, USA) shares with us his insights into the role of endotheliopathy in the development of coagulopathy in patients with COVID-19.
1. How common is coagulopathy in COVID-19 infection and who is at greatest risk? (0:03)
2. What is known about the role of endotheliopathy in the development of coagulopathy in patients with COVID-19? (1:39)
3. What is the link between the inflammatory response to SARS-CoV-2 and endotheliopathy? (2:23)
4. What practical advice would you give to physicians managing coagulopathy in patients with COVID-19 in terms of laboratory monitoring and anticoagulant therapy management? (3:33)
5. What can be done to identify high-risk populations? (5:33)
Abstract LB2605, Endotheliopathy is Essential in COVID-19 Associated Coagulopathy, is available at EHA25 Virtual here.
Speaker disclosure: George Goshua has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media.
Filmed at the Virtual Edition of the 25th European Hematology Association Annual Congress (EHA25 Virtual), June 2020.
COVID-19 = coronavirus disease 2019; SARS CoV-2 = severe acute respiratory syndrome coronavirus 2.
Share this Video
Related Videos In Haematology
Bernd Jilma, ASH 2022: Pegcetacoplan in patients with cold agglutinin disease, the CASCADE phase III trial
The CASCADE trial aims to assess the efficacy and safety of pegcetacoplan in patients with cold agglutinin disease (CAD). In this touchONCOLOGY interview, we speak with Dr Bernd Jilma (Medical University of Vienna, Vienna, Austria) to discuss the CASCADE trial and when results should be expected. The abstract entitled ‘Trial in Progress: Randomized, Double-Blind, Placebo-Controlled […]
Bernd Jilma, ASH 2022: The pathophysiology and unmet treatment needs in cold agglutinin disease
Cold agglutinin disease (CAD) is a rare, autoimmune, clonal B cell disorder. In this touchONCOLOGY interview, we speak with Dr Bernd Jilma (Medical University of Vienna, Vienna, Austria) to discuss the pathophysiology of CAD and the unmet treatment needs in this disease. The abstract entitled ‘Trial in Progress: Randomized, Double-Blind, Placebo-Controlled Multicenter Phase 3 Study […]
Srdan Verstovsek, ASH 2022: Momelotinib long-term safety in myelofibrosis disease – Analysis of SIMPLIFY-1, SIMPLIFY-2, and MOMENTUM trials
Momelotinib, an oral JAK1/JAK2/ACVR1 inhibitor, was evaluated in 3 randomised controlled trials – SIMPLIFY-1, SIMPLIFY-2, and MOMENTUM, in patients with high- and intermediate-risk myelofibrosis. In this touchONCOLOGY interview, we speak with Prof. Srdan Verstovsek (MD Anderson Cancer Center, Houston, TX, USA) to discuss the limitations of JAK inhibitor therapy in myelofibrosis, and the integrated analysis of […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!